Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
8 results loaded, newest first. End of these results.
New On The Block Caribou Biosciences, Inc. (NASDAQ: CRBU ), a clinical-stage CRISPR genome-editing biopharmaceutical company, is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs. The company has hire
Viatris said it will acquire Pacira BioSciences for $1.65 billion in cash, or $36.50 a share, a roughly 45% premium to Pacira's Wednesday close. The deal is expected to close by year-end and was followed by a 44% jump in Pacira shares and a 2.2% decline in Viatris.
Viatris Inc. (NASDAQ: VTRS ) announced Thursday that it agreed to acquire Pacira BioSciences Inc. (NASDAQ: PCRX ) for $1.65 billion, strengthening its position in non-opioid pain management. Under the agreement, Viatris will pay $36.50 per share in cash for all outstanding Pacira shares. Viatris reported $886.5 million
Viatris said it will acquire Pacira BioSciences for $1.65 billion, or $36.50 a share, in cash. The company expects the deal to close by year-end and to have a minimal impact on gross leverage.
Viatris entered into a merger agreement with Pacira BioSciences under which a Viatris subsidiary will launch a tender offer to acquire all Pacira shares for $36.50 each in cash. The deal is subject to customary conditions, including HSR review and a minimum tender condition.
Viatris will pay $36.50 per share in cash for Pacira BioSciences, a roughly 45% premium to Pacira’s prior close, in a deal set to close by year-end.
Viatris to buy Pacira BioSciences for $36.50/share in cash
Viatris (VTRS) has agreed to buy Pacira Biosciences (PCRX) for $1.65B in cash, at $36.50 per share.